Literature DB >> 12126310

Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches.

Kathy P An1, Mohammad Athar, Xiuwei Tang, Santosh K Katiyar, Justin Russo, J Beech, Michelle Aszterbaum, Levy Kopelovich, Ervin H Epstein, Hasan Mukhtar, David R Bickers.   

Abstract

Inflammatory stimuli result in the production of cutaneous eicosanoids, which are known to contribute to the process of tumor promotion. Cyclooxygenase (COX), the rate-limiting enzyme for the production of prostaglandins (PG) from arachidonic acid, exists in at least two isoforms, COX-1 and COX-2. COX-1 is constitutively expressed in most tissues and plays various physiological roles, whereas increased COX-2 expression is known to occur in several types of epithelial neoplasms. Enhanced PG synthesis is a potential contributing factor in UVB-induced nonmelanoma skin cancers (NMSC). Increased COX-2 staining occurs in murine skin neoplasms after chronic exposure to carcinogenic doses of UVB. In this study, immunohistochemical and Western blot analyses were employed to assess longitudinally COX-2 expression in a standard mouse UVB complete carcinogenesis protocol and in human basal cell carcinomas (BCC) and squamous cell carcinomas (SCC). During UVB irradiation of mice, COX-2 expression consistently increased in the hyperplastic skin, the benign papillomas and the SCC. COX-2 expression was also increased in human actinic keratoses, SCC and BCC as well as in murine SCC and BCC. The pattern of COX-2 expression was quite variable, occurring in a patchy distribution in some lesions with staining confined mainly to suprabasal cell layers. In general, COX-2 expression progressively became more extensive in benign papillomas and well-differentiated murine SCC. The staining was predominantly cytoplasmic and perinuclear in some focal areas in tissue stroma around both murine and human tumors. Western blot analysis confirmed negative COX-2 expression in normal skin, whereas acute UVB exposure resulted in increased enzyme expression, which continued to increase in developing papillomas and SCC. Because of the evidence indicating a pathogenic role for eicosanoids in murine and human skin neoplasms, we performed studies to assess the anti-inflammatory and anticarcinogenic effects of green tea extracts, which are potent antioxidants. Acute exposure of the human skin to UVB (minimum erythema dose x 4) caused a transient enhancement of the COX-2 expression, which reverted to baseline within hours; however, in murine skin the expression persisted for several days. Pretreatment with the topically applied green tea extract (1 mg/cm2) largely abrogated the acute COX-2 response to UVB in mice or humans. In summary, enhanced COX-2 expression serves as a marker of epidermal UVB exposure for murine and human NMSC. These results suggest that COX-2 inhibitors could have potent anticarcinogenic effects in UVB-induced skin cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126310     DOI: 10.1562/0031-8655(2002)076<0073:ceimah>2.0.co;2

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  52 in total

Review 1.  Polyphenols: skin photoprotection and inhibition of photocarcinogenesis.

Authors:  F Afaq; S K Katiyar
Journal:  Mini Rev Med Chem       Date:  2011-12       Impact factor: 3.862

2.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

3.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

4.  Effects of ascorbic acid on UV light-mediated photoreceptor damage in isolated rat retina.

Authors:  Kazuhiro Tokuda; Charles F Zorumski; Yukitoshi Izumi
Journal:  Exp Eye Res       Date:  2007-01-12       Impact factor: 3.467

5.  Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

Authors:  Jean Y Tang; Michelle Aszterbaum; Mohammad Athar; Franco Barsanti; Carol Cappola; Nini Estevez; Jennifer Hebert; Jimmy Hwang; Yefim Khaimskiy; Arianna Kim; Ying Lu; Po-Lin So; Xiuwei Tang; Michael A Kohn; Charles E McCulloch; Levy Kopelovich; David R Bickers; Ervin H Epstein
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

6.  Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Authors:  Yira Bermudez; Steven P Stratton; Clara Curiel-Lewandrowski; James Warneke; Chengcheng Hu; George T Bowden; Sally E Dickinson; Zigang Dong; Ann M Bode; Kathylynn Saboda; Christine A Brooks; Emanuel F Petricoin; Craig A Hurst; David S Alberts; Janine G Einspahr
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-01

7.  Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression.

Authors:  Nam Joo Kang; Ki Won Lee; Bong Jik Shin; Sung Keun Jung; Mun Kyung Hwang; Ann M Bode; Yong-Seok Heo; Hyong Joo Lee; Zigang Dong
Journal:  Carcinogenesis       Date:  2008-12-10       Impact factor: 4.944

8.  Cell-type-specific roles for COX-2 in UVB-induced skin cancer.

Authors:  Jing Jiao; Carol Mikulec; Tomo-o Ishikawa; Clara Magyar; Darren S Dumlao; Edward A Dennis; Susan M Fischer; Harvey Herschman
Journal:  Carcinogenesis       Date:  2014-01-27       Impact factor: 4.944

Review 9.  Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.

Authors:  Craig A Elmets; Mohammad Athar
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

Review 10.  Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Authors:  Geoffrey T Gibney; Jane L Messina; Inna V Fedorenko; Vernon K Sondak; Keiran S M Smalley
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.